Last reviewed · How we verify

NCT07056829

The Effect of Mandibular Advancement With Clear Aligners on Maxillary and Mandibular Volumes

Completed NA Last updated 9 July 2025
What this trial tests

NA trial testing Mandibular Advancement Appliance (Invisalign MA) in Mandibular Retrognathia in 55 participants. Completed in 1 June 2025.

Timeline
1 May 2025
Primary endpoint
1 June 2025
1 June 2025

Quick facts

Lead sponsorBatman University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment55
Start date1 May 2025
Primary completion1 June 2025
Estimated completion1 June 2025
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Batman University

Who can join

Eligibility, any sex, with Mandibular Retrognathia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to compare the effectiveness of two different orthodontic treatment methods used in patients with skeletal Class II malocclusion, a condition in which the lower jaw is positioned backward. Approximately 80% of Class II malocclusions are due to mandibular retrusion. Therefore, functional appliances that stimulate mandibular growth in growing individuals have been widely used in orthodontics for many years. In recent years, clear aligner systems have become increasingly popular in orthodontic practice. A mandibular advancement feature was recently integrated into these aligners, allowing for simultaneous tooth alignment and forward positioning of the lower jaw. In this study, the newly developed Mandibular Advancement Appliance (MAA), based on clear aligners, will be compared to the traditional functional appliance known as the Activator. Who Can Participate in the Study? Children with retrusive lower jaws who are in the growth and development period Individuals with no prior orthodontic treatment Patients with specific levels of dental protrusion (overjet) Those with good general health and no contraindications for CBCT imaging What Will the Treatment Process Involve? Participants will be randomly assigned to one of three groups: MAA group (clear aligners with mandibular advancement) Activator group (traditional removable appliance) Control group (no treatment, only observation) The active treatment period will last approximately 7-8 months, followed by a retention phase. All patients will be monitored regularly, and strict adherence to appliance use will be expected. How Will the Outcomes Be Assessed? Before and after the treatment period, participants will undergo cone-beam computed tomography (CBCT) scans to obtain detailed three-dimensional images of the jaws. These images will be analyzed to evaluate volumetric changes. All measurements will be performed by a trained orthodontic specialist using dedicated software. Potential Benefits for Participants: Participants will receive close clinical monitoring throughout the study period. The use of advanced imaging technologies may support the development of more effective and individualized treatment plans. Safety and Confidentiality: This study has received ethical approval and will be conducted in accordance with relevant data protection and research ethics standards. All personal data will be kept confidential. Written informed consent will be obtained from all participants and/or their legal guardians.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The effect of mandibular advancement with clear aligners compared with activator therapy on maxillary and mandibular volumes: a randomized controlled trial using CBCT.
    Kavasoğlu N, Nai̇boğlu E. · · 2026 · PMID 41709259 · DOI 10.1186/s12903-026-07924-4

Verify or expand the search:

Other Batman University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing